Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
Polyclonal anti–T‑cell IgG binds T‑cell antigens (including CD52) and depletes those cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
Polyclonal IgG in rATG binds CD45 on T cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis, also inducing apoptosis, leading to direct depletion of CD45+ T cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
Anti-thymocyte globulin contains antibodies that bind CD29 on T cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis to deplete those cells.
Autologous anti-CD20 CAR T-cell therapy (also known as ELC-301) engineered to express and secrete Helicobacter pylori neutrophil-activating protein (HP-NAP) upon CD20 engagement, enabling direct killing of CD20+ B cells and recruitment/activation of innate immune cells to enhance anti-tumor immunity.
Autologous anti-CD20 CAR T cells that directly kill CD20+ B cells; upon antigen engagement they secrete Helicobacter pylori neutrophil-activating protein (HP-NAP), recruiting and activating innate immune cells (e.g., neutrophils, monocytes/dendritic cells) and promoting Th1/NK responses to enhance bystander anti-tumor immunity.
Anti-CD20 CAR T cells recognize CD20 and directly kill CD20+ cells via T‑cell cytolysis (perforin/granzyme and death‑receptor pathways); secreted HP‑NAP further recruits innate cells to augment bystander killing.
Bispecific IgG1 monoclonal antibody against EGFR and MET that blocks ligand/receptor signaling, promotes receptor internalization and degradation, and induces Fc-mediated ADCC/ADCP.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand binding and receptor phosphorylation/signaling, promotes receptor internalization and degradation, and engages Fc-mediated ADCC/ADCP to suppress and eliminate EGFR/MET-expressing tumor cells.
Amivantamab binds EGFR on target cells and its IgG1 Fc engages FcγR-bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC and ADCP, killing EGFR-expressing cells; it also blocks signaling/internalizes receptors (antiproliferative).